

# Company Heartbeats

**Swiss companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
30 Apr 25	Idorsia	Q1 result	CHF 1.18	Call	<a href="#">UBJTSU</a>	19 Sep 25	0.33	2.50	0.20	<a href="#">Calls on Idorsia</a>
30 Apr 25	AMS	Q1 result	CHF 6.99	Call	<a href="#">B8RSTU</a>	19 Sep 25	3.04	7.50	0.61	<a href="#">Calls on AMS</a>
05 May 25	SIG Combibloc	Q1 result	CHF 15.85	Call	<a href="#">B5QXSU</a>	19 Sep 25	7.26	17.00	0.09	<a href="#">Calls on SIG Combibloc</a>
06 May 25	Geberit	Q1 result	CHF 564.80	Call	<a href="#">UBVFSU</a>	19 Sep 25	9.50	600.00	0.22	<a href="#">Calls on Geberit</a>
				Put	<a href="#">B98S5U</a>	19 Sep 25	7.32	540.00	0.27	<a href="#">Puts on Geberit</a>
08 May 25	Swisscom	Q1 result	CHF 545.00	Call	<a href="#">BEKSIU</a>	19 Sep 25	12.85	570.00	0.14	<a href="#">Calls on Swisscom</a>
				Put	<a href="#">BXL5YU</a>	19 Sep 25	12.46	520.00	0.14	<a href="#">Puts on Swisscom</a>
08 May 25	Adecco	Q1 result	CHF 21.96	Call	<a href="#">BC7STU</a>	19 Sep 25	6.07	23.00	0.17	<a href="#">Calls on Adecco</a>
09 May 25	Sandoz	Q1 result	CHF 36.60	Call	<a href="#">BHNSUU</a>	19 Sep 25	7.02	38.00	0.24	<a href="#">Calls on Sandoz</a>
13 May 25	Alcon	Q1 result	CHF 79.30	Call	<a href="#">BBDSIU</a>	19 Sep 25	8.74	82.00	0.39	<a href="#">Calls on Alcon</a>
				Put	<a href="#">BTBSOU</a>	19 Sep 25	7.93	75.00	0.34	<a href="#">Puts on Alcon</a>
16 May 25	Swiss Re	Q1 result	CHF 144.25	Call	<a href="#">BHVSMU</a>	19 Sep 25	8.78	150.00	0.46	<a href="#">Calls on Swiss Re</a>
				Put	<a href="#">B2ZSUU</a>	19 Sep 25	7.69	140.00	0.50	<a href="#">Puts on Swiss Re</a>
19 May 25	Zurich Insurance	Q1 result	CHF 570.40	Call	<a href="#">BF8SLU</a>	19 Sep 25	12.36	590.00	0.36	<a href="#">Calls on Zurich Insurance</a>
				Put	<a href="#">B9ZSUU</a>	19 Sep 25	11.11	550.00	0.38	<a href="#">Puts on Zurich Insurance</a>
04 Jun 25	VAT Group	Q1 result	CHF 296.70	Call	<a href="#">B33S9U</a>	19 Sep 25	5.65	320.00	0.21	<a href="#">Calls on VAT Group</a>
11 Jun 25	Galenica	Q1 result	CHF 85.20	Call	<a href="#">UBMYSU</a>	19 Sep 25	9.74	90.00	0.14	<a href="#">Calls on Galenica</a>

Source: Refinitiv, UBS.

As of: 29 Apr 25. All prices are indicative.

# Company Heartbeats

**International companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
30 Apr 25	Meta Platforms	Q1 result	USD 549.74	Call	<a href="#">BJOSQU</a>	19 Sep 25	6.57	570.00	0.87	<a href="#">Calls on Meta Platforms</a>
30 Apr 25	Microsoft	Q3 result	USD 391.16	Call	<a href="#">BX1SIU</a>	19 Sep 25	10.00	410.00	0.36	<a href="#">Calls on Microsoft</a>
30 Apr 25	Volkswagen	Q1 result	EUR 98.62	Call	<a href="#">BK5SUU</a>	19 Sep 25	15.78	110.00	0.04	<a href="#">Calls on Volkswagen</a>
01 May 25	Amazon	Q1 result	USD 187.70	Call	<a href="#">BFFS9U</a>	19 Sep 25	7.36	195.00	0.26	<a href="#">Calls on Amazon</a>
01 May 25	Eli Lilly	Q1 result	USD 877.29	Call	<a href="#">B56SHU</a>	19 Sep 25	6.39	950.00	0.46	<a href="#">Calls on Eli Lilly</a>
01 May 25	Apple	Semi-annual report	USD 210.14	Call	<a href="#">BBPSLU</a>	19 Sep 25	8.59	220.00	0.23	<a href="#">Calls on Apple</a>
01 May 25	Moderna	Q1 result	USD 27.46	Call	<a href="#">BV4SIU</a>	19 Sep 25	3.94	29.00	0.39	<a href="#">Calls on Moderna</a>
02 May 25	Shell	Q1 result	EUR 28.75	Call	<a href="#">BNXSRU</a>	19 Sep 25	12.94	30.00	0.20	<a href="#">Calls on Shell</a>
06 May 25	AMD	Q1 result	USD 96.39	Call	<a href="#">BFBS1U</a>	19 Sep 25	5.31	100.00	0.49	<a href="#">Calls on AMD</a>
07 May 25	Barrick Gold	Q1 result	USD 19.30	Call	<a href="#">BQPSFU</a>	19 Sep 25	7.72	20.00	0.25	<a href="#">Calls on Barrick Gold</a>
09 May 25	Commerzbank	Q1 result	EUR 23.56	Call	<a href="#">B5OS2U</a>	19 Sep 25	6.74	25.00	0.40	<a href="#">Calls on Commerzbank</a>
12 May 25	Alibaba	Annual report	USD 118.37	Call	<a href="#">B5ASRU</a>	19 Sep 25	6.36	130.00	0.40	<a href="#">Calls on Alibaba</a>

Source: Refinitiv, UBS.

As of: 29 Apr 25. All prices are indicative.

## Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

**Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).**

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website [keyinvest.ch/en.ubs.com](https://keyinvest.ch/en.ubs.com), by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2025. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

## Contact

[keyinvest@ubs.com](mailto:keyinvest@ubs.com)

+41 44 239 76 76\*

[ubs.com/keyinvest](https://ubs.com/keyinvest)

\*Please note that calls to numbers marked with \* may be recorded. When you call these numbers, we assume that you consent to this practice.